Sun Pharma to defend antitrust claims over delayed entry of 3 generic drugs in US

Sun Pharma to defend antitrust claims over delayed entry of 3 generic drugs in US Sun Pharma said the litigation had already been disclosed in the company#39;s FY19 annual report.

No comments:

Post a Comment